Oncor disappears from the Amex:
This article was originally published in Clinica
Executive Summary
Oncor, the troubled gene-based diagnostic company, has had its shares suspended indefinitely from the American Stock Exchange (AMEX). AMEX had already applied to the Securities and Exchange Commission to remove Oncor from the market - a move that Oncor had opposed. Now, Oncor's failing liquidity (see Clinica No 828, p 9) has prompted the delisting. It is not known whether the Gaithersburg, Maryland, company will attempt to get a quote on one of the alternative markets.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.